Zolgensma
Biological Gene Therapy
General payments
$1,548,869
Research payments
$6,244,303
Through program year 2023, $1,548,869 in general payments and $6,244,303 in research payments were reported against Zolgensma (Gene Therapy).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
10 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | General | $211,615 | 326 |
| 2023 | Research | $326,818 | 73 |
| 2022 | General | $185,531 | 443 |
| 2022 | Research | $619,182 | 89 |
| 2021 | General | $145,244 | 289 |
| 2021 | Research | $623,144 | 114 |
| 2020 | General | $462,067 | 977 |
| 2020 | Research | $1,825,424 | 337 |
| 2019 | General | $544,412 | 1,568 |
| 2019 | Research | $2,849,734 | 195 |
Breakdown
The top 5 of 91 recipients; each share is of general payments naming this product in 2023.
The top 5 of 20 specialties; each share is of general payments naming this product to practitioners with a specialty in 2023. Each practitioner is counted under their primary specialty.
The top 5 of 30 states; each share is of general payments naming this product in 2023 where a state was reported.
Records
3,603 general · 808 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.